Compare EPAC & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | NVCR |
|---|---|---|
| Founded | 1910 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | EPAC | NVCR |
|---|---|---|
| Price | $37.07 | $12.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $50.50 | $28.42 |
| AVG Volume (30 Days) | 543.2K | ★ 1.9M |
| Earning Date | 12-17-2025 | 10-30-2025 |
| Dividend Yield | ★ 0.11% | N/A |
| EPS Growth | ★ 0.98 | N/A |
| EPS | ★ 1.66 | N/A |
| Revenue | $615,911,000.00 | ★ $642,269,000.00 |
| Revenue This Year | $6.18 | $9.75 |
| Revenue Next Year | $5.58 | $5.62 |
| P/E Ratio | $22.41 | ★ N/A |
| Revenue Growth | 3.91 | ★ 11.17 |
| 52 Week Low | $35.01 | $10.70 |
| 52 Week High | $47.47 | $32.06 |
| Indicator | EPAC | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 53.97 |
| Support Level | $35.01 | $12.30 |
| Resistance Level | $41.73 | $13.94 |
| Average True Range (ATR) | 1.21 | 0.60 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 31.84 | 64.92 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.